Description: BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures' and ArsciCor, which is in Phase III in GvHD is being prepared with an oral treatment. BioSenic S.A. is based in Mont-Saint-Guibert, Belgium.
Home Page: www.biosenic.com
Building H (box 24)
Mont-Saint-Guibert,
1435
Belgium
Phone:
32 493 09 73 66
Officers
| Name | Title |
|---|---|
| Ms. Alexia Rieger | Chief Investor Relation Officer |
| Dr. Lieven Huysse M.D. | Chief Medical Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 7.3842 |
| Price-to-Sales TTM: | 0.5635 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |